Anti-aminoacyl-tRNA synthetase (ARS) and anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are closely associated with interstitial lung disease in polymyositis and dermatomyositis. Anti-ARS-positive patients develop common clinical characteristics termed anti-synthetase syndrome and share a common clinical course, in which they respond well to initial treatment with glucocorticoids but in which disease tends to recur when glucocorticoids are tapered. Anti-MDA5 antibody is associated with rapidly progressive interstitial lung disease and poor prognosis, particularly in Asia. Therefore, intensive immunosuppressive therapy is required for anti-MDA5-positive patients from the early phase of the disease. New enzyme-linked immunosorbent assays to detect anti-ARS and anti-MDA5 antibodies have recently been established and are suggested to be efficient and useful. These assays are expected to be widely applied in daily practice.
KaoAHLacomisDLucasMFertigNOddisCV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum2004; 50: 209–215.
2.
ReevesWHNigamSKBlobelG. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA1986; 83: 9507–9511.
3.
TargoffINJohnsonAEMillerFW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum1990; 33: 1361–1370.
4.
TargoffINReichlinM. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum1985; 28: 796–803.
KajiKFujimotoMHasegawaM. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford)2007; 46: 25–28.
7.
TargoffINMamyrovaGTrieuEP. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum2006; 54: 3682–3689.
8.
CeribelliAFrediMTaraborelliM. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther2012; 14: R97–R97.
9.
EspadaGMaldonado CoccoJAFertigNOddisCV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol2009; 36: 2547–2551.
10.
GunawardenaHWedderburnLRChinoyH. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum2009; 60: 1807–1814.
11.
IchimuraYMatsushitaTHamaguchiY. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis2012; 71: 710–713.
12.
AllenbachYDrouotLRigoletA. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore)2014; 93: 150–157.
13.
GeYLuXPengQShuXWangG. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One2015; 10: e0141616–e0141616.
14.
MammenALChungTChristopher-StineL. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum2011; 63: 713–721.
15.
BetteridgeZEGunawardenaHChinoyH. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis2009; 68: 1621–1625.
16.
MuroYSugiuraKAkiyamaM. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity2013; 46: 279–284.
17.
TarriconeEGhirardelloARampuddaMBassiNPunziLDoriaA. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods2012; 384: 128–134.
18.
Schulte-PelkumJFritzlerMMahlerM. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev2009; 8: 632–637.
19.
IkedaNTakahashiKYamaguchiYInasakaMKuwanaMIkezawaZ. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol2011; 38: 973–979.
20.
HozumiHEnomotoNKonoM. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS One2015; 10: e0120313–e0120313.
21.
GonoTKanekoHKawaguchiY. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford)2014; 53: 2196–2203.
22.
Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68: 689–694.
23.
NishikaiMReichlinM. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum1980; 23: 881–888.
24.
MathewsMBBernsteinRM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature1983; 304: 177–179.
25.
MathewsMBReichlinMHughesGRBernsteinRM. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med1984; 160: 420–434.
26.
BunnCCBernsteinRMMathewsMB. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med1986; 163: 1281–1291.
27.
TargoffINTrieuEPPlotzPHMillerFW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum1992; 35: 821–830.
28.
TargoffINTrieuEPMillerFW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest1993; 91: 2556–2564.
29.
HirakataMSuwaANagaiS. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol1999; 162: 2315–2320.
30.
BetteridgeZGunawardenaHNorthJSlinnJMcHughN. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford)2007; 46: 1005–1008.
31.
HashishLTESadanandanPTargoffIN. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome [abstract]. Arthritis Rheum2005; 52: S312–S312.
32.
YoshifujiHFujiiTKobayashiS. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity2006; 39: 233–241.
33.
HamaguchiYFujimotoMMatsushitaT. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One2013; 8: e60442–e60442.
34.
LegaJCFabienNReynaudQ. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev2014; 13: 883–891.
35.
NakashimaRImuraYHosonoY. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One2014; 9: e85062–e85062.
36.
WatanabeKHandaTTanizawaK. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med2011; 105: 1238–1247.
37.
TanizawaKHandaTNakashimaR. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med2011; 105: 1380–1387.
38.
TakatoHWasedaYWatanabeS. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia – with or without PM/DM. Respir Med2013; 107: 128–133.
39.
AggarwalRCassidyEFertigN. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis2014; 73: 227–232.
40.
HervierBDevilliersHStanciuR. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev2012; 12: 210–217.
41.
YeSChenXXLuXY. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol2007; 26: 1647–1654.
SatoSHirakataMKuwanaM. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum2005; 52: 1571–1576.
44.
SatoSHoshinoKSatohTFujitaTKawakamiYKuwanaM. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum2009; 60: 2193–2200.
45.
NakashimaRImuraYKobayashiS. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford)2010; 49: 433–440.
46.
HoshinoKMuroYSugiuraKTomitaYNakashimaRMimoriT. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford)2010; 49: 1726–1733.
47.
ChenFWangDShuXNakashimaRWangG. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int2012; 32: 3909–3915.
48.
KogaTFujikawaKHoraiY. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford)2012; 51: 1278–1284.
49.
FiorentinoDChungLZwernerJRosenACasciola-RosenL. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol2011; 65: 25–34.
50.
CeribelliAFrediMTaraborelliM. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol2014; 32: 891–897.
51.
Labrador-HorrilloMMartinezMASelva-O’CallaghanA. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res2014; 2014: 290797–290797.
52.
HallJCCasciola-RosenLSamedyLA. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken)2013; 65: 1307–1315.
53.
GonoTKawaguchiYKuwanaM. Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum2012; 64: 3736–3740.
54.
MuroYSugiuraKHoshinoKAkiyamaMTamakoshiK. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther2011; 13: R214–R214.
55.
HosonoYNakashimaRImuraY. The onsets of myositis with myositis-specific autoantibodies (MSAs) are associated with the seasons. Ann Rheum Dis2013; 72(Suppl 3): 656–656.
56.
KobayashiIOkuraYYamadaMKawamuraNKuwanaMArigaT. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr2011; 158: 675–677.
57.
IkedaSAritaMMoritaM. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?BMC Pulm Med2015; 15: 159–159.
58.
TansleySLBetteridgeZEGunawardenaH. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther2014; 16: R138–R138.
59.
GonoTKawaguchiYOzekiE. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol2011; 21: 223–227.
60.
GonoTSatoSKawaguchiY. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford)2012; 51: 1563–1570.
GonoTKanekoHKawaguchiY. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford)2014; 53: 2196–2203.
63.
HoraiYKogaTFujikawaK. Serum interferon-alpha is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol2015; 25: 85–89.
64.
KamedaHNagasawaHOgawaH. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol2005; 32: 1719–1726.
65.
TanakaFOriguchiTMigitaK. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med2000; 39: 428–430.
66.
NakashimaRHosonoYYukawaN. Clinical features and treatment of dermatomyositis patients with anti-CADM-140 (melanoma differentiation-associated protein 5: MDA5) antibody: recommendation of combined immunosuppressive therapy with intensive intravenous cyclophosphamide. Arthritis Rheum2011; 63: S225–S225.
67.
KatoHTakeuchiOSatoS. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature2006; 441: 101–105.
68.
BowlesNEDubowitzVSewryCAArchardLC. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet1987; 1: 1004–1007.
69.
ChevrelGCalvetABelinVMiossecP. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford)2000; 39: 1037–1039.
70.
ChristensenMLPachmanLMSchneidermanRPatelDCFriedmanJM. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum1986; 29: 1365–1370.
71.
AschermanDP. Role of Jo-1 in the immunopathogenesis of the anti-synthetase syndrome. Curr Rheumatol Rep2015; 17: 56–56.
72.
OkiyamaNSugiharaTOidaT. T lymphocytes and muscle condition act like seeds and soil in a murine polymyositis model. Arthritis Rheum2012; 64: 3741–3749.
73.
FormanMSNakamuraMMimoriTGelpiCHardinJA. Detection of antibodies to small nuclear ribonucleoproteins and small cytoplasmic ribonucleoproteins using unlabeled cell extracts. Arthritis Rheum1985; 28: 1356–1361.
74.
GhirardelloABendoRRampuddaMEBassiNZampieriSDoriaA. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev2009; 8: 645–649.
75.
GhirardelloARampuddaMEkholmL. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford)2010; 49: 2370–2374.
76.
TargoffIN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol1990; 144: 1737–1743.
77.
QuevillonSRobinsonJCBerthonneauESiateckaMMirandeM. Macromolecular assemblage of aminoacyl-tRNA synthetases: identification of protein–protein interactions and characterization of a core protein. J Mol Biol1999; 285: 183–195.
78.
MahlerMMillerFWFritzlerMJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev2014; 13: 367–371.
79.
SatoSKuwanaMFujitaTSuzukiY. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol2013; 23: 496–502.
